

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### STA Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Final draft guidance

(when no draft guidance was issued)

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

No potential equality issues have been identified during the scoping process.
---

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

The company outlined that there are barriers related to the delivery of CAR T-cell therapies, with many patients being unable, or having to travel long distances, to access therapy centres. The committee agreed that access was an issue with CAR T-cell therapies, but that access to therapy centres could not be addressed through its recommendations. The committee's recommendations allow access to an additional treatment option that does not require travel to a specialist centre.
---

- |  |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

No other issues were raised by the committee

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

The recommendations will not lead to access difficulties for specific groups of people

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

The recommendations are unlikely to have an adverse impact on people with disabilities

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

None

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

Yes, they are contained within section 3.17 of the guidance document

**Approved by Associate Director (name):** Ross Dent

**Date:** 31/08/2023

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments

2 of 2

Issue date: August 2023